News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
It would be the first protein-based alternative available in Israel
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Biocon has reported consolidated financial results for the period ended December 31, 2021
First launches expected in H1 2022
Subscribe To Our Newsletter & Stay Updated
